专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO9705906A3 DIAGNOSTIC AND DIAGNOSIS METHOD FOR CENTRAL NERVOUS ABNORMALITY AND PHENYLKETONURIA 审中-公开
标题翻译：诊断和诊断方法用于中枢神经不正常和苯丙酮
公开(公告)号：WO9705906A3
公开(公告)日：1997-05-29
申请号：PCT/JP9602206
申请日：1996-08-06
申请人： OTSUKA PHARMA CO LTD , KAJIWARA MASAHIRO , HIROSE TSUYOSHI , IKEI NOBUHIRO
发明人： KAJIWARA MASAHIRO , HIROSE TSUYOSHI , IKEI NOBUHIRO
IPC分类号： G01N27/62 , A61K49/00 , A61K51/12 , G01N33/497 , G01N33/50 , G01N33/60 , G01R33/465
CPC分类号： A61K51/1206 , A61K2123/00
摘要： There is provided a diagnostic for central nervous abnormality, comprising a labeled transmitter substance of central nervous system or a labeled precursor of the transmitter substance, whose at least one of carbon atoms is substituted for a carbon isotope wherein the diagnostic is useful for diagnosing a central nervous abnormality (e.g. depression, Alzheimer's disease, schizophrenia, etc.) by applying it to a living body by oral administration or injection and examining a change in an amount of the carbon isotope in a breath of the living body.
摘要翻译： PCT No.PCT / JP96 / 02206 Sec。 371日期1997年04月1日 102（e）1997年4月1日PCT 1996年8月6日PCT PCT。出版物WO97 / 05906 日期1997年2月20日提供了对中枢神经异常的诊断，包括中枢神经系统的标记的发射物质或发射物质的标记的前体，其至少一个碳原子被碳同位素代替，其中诊断是可用于通过口服或注射施用于生物体来检测中枢神经异常（例如抑郁症，阿尔茨海默病，精神分裂症等），并检查活体内的呼吸中碳同位素的量的变化。

2. 发明申请

WO2004105682A3 CARBOSTYRIL DERIVATIVES AND MOOD STABILIZERS FOR TREATING MOOD DISORDERS 审中-公开
标题翻译： CARBOSTYRIL衍生物和用于治疗疾病的MOOD STABILIZERS
公开(公告)号：WO2004105682A3
公开(公告)日：2005-05-12
申请号：PCT/US2004013308
申请日：2004-05-19
申请人： OTSUKA PHARMA CO LTD , KIKUCHI TETSURO , IWAMOTO TARO , HIROSE TSUYOSHI
发明人： KIKUCHI TETSURO , IWAMOTO TARO , HIROSE TSUYOSHI
IPC分类号： A61K20060101 , A61K31/19 , A61K31/47 , A61K31/497 , A61K31/519 , A61K33/14 , A61K45/06
CPC分类号： A61K31/496 , A61K31/19 , A61K31/195 , A61K31/357 , A61K31/4015 , A61K31/423 , A61K31/425 , A61K31/4704 , A61K31/497 , A61K31/53 , A61K31/55 , A61K31/5513 , A61K31/7008 , A61K33/00 , A61K33/14 , A61K45/06 , A61K2300/00
摘要： The pharmaceutical composition of the present invention comprises a carbostyril derivative which is a dopamine-serotonin system stabilizer and a mood stabilizer in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof. The mood stabilizer may include but is not limited to lithium, valproic acid, divalproex sodium, carbamazapine, oxcarbamazapine, zonisamide, lamotragine, topiramate, gabapentin, levetiracetam or clonazepam. These compositions are used to treat patients with mood disorders, particularly bipolar disorder with or without psychotic features, mania or mixed episodes. Methods are provided for separate administration of a carbostyril derivative and a mood stabilizer to a patient with a mood disorder.
摘要翻译：本发明的药物组合物包含作为多巴胺 - 血清素系统稳定剂的喹诺酮衍生物和药学上可接受的载体中的情绪稳定剂。喹诺酮类衍生物可以是阿立哌唑或其代谢物。情绪稳定剂可以包括但不限于锂，丙戊酸，二丙酸钠，卡马西平，奥卡马沙平，唑尼沙胺，拉莫司定，托吡酯，加巴喷丁，左乙拉西坦或氯硝西泮。这些组合物用于治疗情绪障碍的患者，特别是伴有或没有精神病特征，躁狂或混合发作的双相情感障碍。提供了用于将单独施用喹诺酮衍生物和情绪稳定剂给患有情绪障碍的患者的方法。

3. 发明申请

WO02060423A3 SUBSTITUTED CARBOSTYRIL DERIVATIVES AS 5-HT1A RECEPTOR SUBTYPE AGONISTS 审中-公开
标题翻译：作为5-HT1A受体亚型激动剂的替代卡博林衍生物
公开(公告)号：WO02060423A3
公开(公告)日：2003-04-10
申请号：PCT/JP0200626
申请日：2002-01-29
申请人： OTSUKA PHARMA CO LTD
发明人： JORDAN SHAUN , KIKUCHI TETSURO , TOTTORI KATSURA , HIROSE TSUYOSHI , UWAHODO YASUFUMI
IPC分类号： C07D215/22 , A61K31/00 , A61K31/496 , A61K45/06 , A61P1/08 , A61P3/04 , A61P15/00 , A61P15/10 , A61P25/02 , A61P25/06 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/24 , A61P25/28 , A61P25/30 , A61P39/02
CPC分类号： A61K31/00 , A61K31/496 , A61K45/06 , A61K2300/00
摘要： The present invention relates to use of a compound for the production of a medicament for treating a patient suffering from a disorder of the central nervous system associated with 5-HT1A receptor subtype, which the medicament comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1), wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond; and a pharmaceutically acceptable salt or solvate thereof.
摘要翻译：本发明涉及化合物在制备用于治疗患有与5-HT 1A受体亚型相关的中枢神经系统疾病的患者的药物中的用途，所述药物包含喹诺酮衍生物或盐由式（1）表示，其中喹诺酮骨架中3-和4-位之间的碳 - 碳键是单键或双键; 及其药学上可接受的盐或溶剂合物。

4. 发明公开

EP1626721A4 CARBOSTYRIL DERIVATIVES AND MOOD STABILIZERS FOR TREATING MOOD DISORDERS 有权
标题翻译：喹诺酮情绪障碍的BEHANLDUNG衍生物和情绪稳定剂
公开(公告)号：EP1626721A4
公开(公告)日：2008-06-18
申请号：EP04785621
申请日：2004-05-19
申请人： OTSUKA PHARMA CO LTD
发明人： KIKUCHI TETSURO , IWAMOTO TARO , HIROSE TSUYOSHI
IPC分类号： A61K31/47 , A61K20060101 , A61K31/19 , A61K31/497 , A61K31/519 , A61K33/14 , A61K45/06
CPC分类号： A61K31/496 , A61K31/19 , A61K31/195 , A61K31/357 , A61K31/4015 , A61K31/423 , A61K31/425 , A61K31/4704 , A61K31/497 , A61K31/53 , A61K31/55 , A61K31/5513 , A61K31/7008 , A61K33/00 , A61K33/14 , A61K45/06 , A61K2300/00

5. 发明专利

EA035837B1 ЛЕКАРСТВЕННОЕ СРЕДСТВО ДЛЯ ПРОФИЛАКТИКИ ИЛИ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ, А ТАКЖЕ СПОСОБЫ ЕГО ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ 未知
公开(公告)号：EA035837B1
公开(公告)日：2020-08-19
申请号：EA201391450
申请日：2012-04-04
申请人： OTSUKA PHARMA CO LTD
发明人： HIROSE TSUYOSHI , MAEDA KENJI , KIKUCHI TETSURO , TODA MASAFUMI
IPC分类号： A61K31/496 , A61K31/00 , A61P25/00
摘要： Изобретениеотноситсяк лекарственномусредствудляпрофилактикиилилечениязаболеванияцентральнойнервнойсистемы, содержащемусоединение (I), котороепредставляетсобой 7-[4-(4-бензо[b]тиофен-4-илпиперазин-1-ил)бутокси]-1H-хинолин-2-онилиегосоль, ипоменьшеймереоднолекарственноесредство (II), выбранноеизгруппы, состоящейизингибитораобратногозахватасеротонина, ингибитораобратногозахватасеротонинаи норэпинефринаи анксиолитическоголекарственногосредства, гдеуказанныйингибиторобратногозахватасеротонинапредставляетсобойпоменьшеймереоднолекарственноесредство, выбранноеизгруппы, состоящейизфлуоксетина, флувоксамина, пароксетина, сертралина, эсциталопрамаи ихсолей; указанныйингибиторобратногозахватасеротонинаи норэпинефринапредставляетсобойпоменьшеймереоднолекарственноесредство, выбранноеизгруппы, состоящейизвенлафаксина, дулоксетина, милнаципрана, десвенлафаксинаи ихсолей; иуказанноеанксиолитическоелекарственноесредствопредставляетсобойдиазепамилиегосоль. Указанноелекарственноесредствоимеетболееширокийспектрлечения, вызываетменьшепобочныхэффектови обладаетпревосходнойпереносимостьюи безопасностьюпосравнениюс известнымитипичнымиантипсихотическимисредствамии атипичнымиантипсихотическимисредствами.

6. 发明专利

SI2694043T1 KOMBINACIJE, OBSEGAJOČE BREKSPIPRAZOL ALI SOL LE-TEGA IN DRUGO ZDRAVILO ZA UPORABO PRI ZDRAVLJENJU MOTNJE CENTRALNEGA ŽIVČNEGA SISTEMA 未知
公开(公告)号：SI2694043T1
公开(公告)日：2018-03-30
申请号：SI201231192
申请日：2012-04-04
申请人： OTSUKA PHARMA CO LTD
发明人： HIROSE TSUYOSHI , MAEDA KENJI , KIKUCHI TETSURO , TODA MASAFUMI
IPC分类号： A61K31/00 , A61P25/00

7. 发明专利

MY152919A CARBOSTYRIL DERIVATIVES AND SEROTONIN REUPTAKE INHIBITORS FOR TREATMENT OF MOOD DISORDERS 未知
公开(公告)号：MY152919A
公开(公告)日：2014-12-15
申请号：MYPI20085175
申请日：2008-12-19
申请人： OTSUKA PHARMA CO LTD
发明人： KIKUCHI TETSURO , IWAMOTO TARO , HIROSE TSUYOSHI
IPC分类号： A61K45/06 , C07D215/00 , A61K31/135 , A61K31/15 , A61K31/165 , A61K31/343 , A61K31/381 , A61K31/4525 , A61K31/47 , A61K31/496 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/28
摘要： THE PHARMACEUTICAL COMPOSITION OF THE PRESENT INVENTION COMPRISES (1) A CARBOSTYRIL DERIVATIVE AND (2) A SEROTONIN REUPTAKE INHIBITOR IN A PHARMACEUTICALLY ACCEPTABLE CARRIER. THE CARBOSTYRIL DERIVATIVE MAY BE ARIPIPRAZOLE OR A METABOLITE THEREOF, WHICH IS A DOPAMINE-SEROTONIN SYSTEM STABILIZER. THE SEROTONIN REUPTAKE INHIBITOR MAY BE FLUOXETINE, DULOXETINE, VENLAFAXINE, MILNACIPRAN, CITALOPRAM, FLUVOXAMINE, PAROXETINE OR SERTRALINE. THE PHARMACEUTICAL COMPOSITION OF THE PRESENT INVENTION IS USEFUL FOR TREATING PATIENTS WITH MOOD DISORDERS, PARTICULARLY DEPRESSION OR MAJOR DEPRESSIVE DISORDER.

8. 发明专利

SG193468A1 COMBINATIONS COMPRISING BREXPIPRAZOLE OR A SALT THEREOF AND A SECOND DRUG FOR USE IN THE TREATMENT OF A CNS DISORDER 未知
公开(公告)号：SG193468A1
公开(公告)日：2013-10-30
申请号：SG2013069273
申请日：2012-04-04
申请人： OTSUKA PHARMA CO LTD
发明人： HIROSE TSUYOSHI , MAEDA KENJI , KIKUCHI TETSURO , TODA MASAFUMI
摘要： The present invention provides a medicament having a wider treatment spectrum, causing a fewer side effects and superior in tolerability and safety, as compared to known typical antipsychotic agents and atypical antipsychotic agents. The present invention related to a medicament containing (I) a compound which is 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, and (II) at least one drug selected from the group consisting of a mood stabilizer, a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor, a noradrenergic and specific serotonergic antidepressant, an antianxiety drug, a tricyclic antidepressant, a tetracyclic antidepressant, an antipsychotic drug and an anti-ADHD drug, in combination.

9. 发明专利

AR085840A1 MEDICAMENTO QUE CONTIENE UN COMPUESTO QUE ES 7-[4-(4-BENZO[B]TIOFEN-4-IL-PIPERAZIN-1-IL)BUTOXI]-1H-QUINOLIN-2-ONA 未知
公开(公告)号：AR085840A1
公开(公告)日：2013-10-30
申请号：ARP120101135
申请日：2012-04-03
申请人： OTSUKA PHARMA CO LTD
发明人： HIROSE TSUYOSHI , MAEDA KENJI , KIKUCHI TETSURO , TODA MASAFUMI
IPC分类号： A61K31/496 , A61P25/00
摘要： Un medicamento que contiene (I) un compuesto que es 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1H-quinolin-2-ona o una de sus sales y (II) al menos un fármaco seleccionado del grupo que consiste en un estabilizador del estado de ánimo, un inhibidor de recaptación de serotonina, un inhibidor de recaptación de norepinefrina, un inhibidor de recaptación de serotonina y norepinefrina, un antidepresivo noradrenérgico y serotonérgico específico, un fármaco antiansiedad, un antidepresivo tricíclico, un antidepresivo tetracíclico, un fármaco antipsicótico y un fármaco anti-ADHD, en combinación.Reivindicación 5: El medicamento de acuerdo con la reivindicación 4, caracterizado porque dicho estabilizador del estado de ánimo es al menos un fármaco seleccionado de litio, valproato de sodio, divalproex sódico, carbamazepina, oxcarbazepina, zonisamida, lamotrigina, topiramato, gabapentina, levetiracetam, clonazepam, fenitoína, pregabalina, hormona tiroidea, tiagabina, ácido graso omega-3 y sus sales. Reivindicación 7: El medicamento de acuerdo con la reivindicación 6, caracterizado porque dicho inhibidor de la recaptación de serotonina es al menos un fármaco seleccionado del grupo que consiste en fluoxetina, citalopram, fluvoxamina, paroxetina, sertralina, escitalopram y sus sales. Reivindicación 8: El medicamento de acuerdo con cualquiera de las reivindicaciones 1 a 3, caracterizado porque dicho fármaco de (II) es un inhibidor de recaptación de norepinefrina. Reivindicación 11: El medicamento de acuerdo con la reivindicación 10, caracterizado porque dicho inhibidor de la recaptación de serotonina y norepinefrina es al menos un fármaco seleccionado del grupo que consiste en venlafaxina, duloxetina, milnaciprano, desvenlafaxina y sus sales. Reivindicación 13: El medicamento de acuerdo con la reivindicación 12, caracterizado porque dicho antidepresivo noradrenérgico y serotonérgico específico es al menos un fármaco seleccionado del grupo que consiste en mirtazapina y una de sus sales. Reivindicación 14: El medicamento de acuerdo con cualquiera de las reivindicaciones 1 a 3, caracterizado porque dicho fármaco de (II) es un fármaco antiansiedad. Reivindicación 15: El medicamento de acuerdo con la reivindicación 14, caracterizado porque dicho fármaco antiansiedad es al menos un fármaco seleccionado del grupo que consiste en un fármaco antiansiedad de benzodiazepina y un fármaco antiansiedad agonista del receptor de serotonina 5-HT1A. Reivindicación 16: El medicamento de acuerdo con la reivindicación 15, caracterizado porque dicho fármaco antiansiedad de benzodiazepina es al menos un fármaco seleccionado del grupo que consiste en diazepam, lorazepam, clorodiazepóxido, cloxazolam, clotiazepam, alprazolam, etizolam, oxazolam y sus sales y dicho fármaco antiansiedad agonista del receptor de serotonina 5-HT1A es al menos un fármaco seleccionado del grupo que consiste en tandospirona, buspirona y sus sales. Reivindicación 18: El medicamento de acuerdo con la reivindicación 17, caracterizado porque dicho fármaco anti-ADHD es al menos un fármaco seleccionado del grupo que consiste en metilfenidato, dexmetilfenidato, atomoxetina, dextroamfetamina, sales mixtas de anfetamina, modafinilo, guanfacina, clonidina y sus sales.

10. 发明专利

CA2716966C CARBOSTYRIL DERIVATIVES AND SEROTONIN REUPTAKE INHIBITORS FOR TREATMENT OF MOOD DISORDERS 未知
公开(公告)号：CA2716966C
公开(公告)日：2012-12-18
申请号：CA2716966
申请日：2003-12-25
申请人： OTSUKA PHARMA CO LTD
发明人： KIKUCHI TETSURO , IWAMOTO TARO , HIROSE TSUYOSHI
IPC分类号： A61K31/496 , A61K45/06 , A61K31/135 , A61K31/137 , A61K31/15 , A61K31/165 , A61K31/343 , A61K31/381 , A61K31/4525 , A61K31/495 , A61P25/00 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/28
摘要： The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式